Skip to main content
. 2012 Mar 9;30(6):2384–2390. doi: 10.1007/s10637-012-9808-8

Table 2.

Treatment efficacy and survival analysis

Duration of Prior Sorafenib Treatment (months)
Median (range) 2.76 (2.12–6.18)
Number of B + E Treatment Cycles
 1 0 (0 %)
 2 2 (20 %)
 3 8 (80 %)
Overall Survival (months)
 Median (95 % C.I.) 4.37 (1.08, 11.66)
Progression-free Survival (months)
 Median (95 % C.I.) 1.51 (1.08, 1.74)